Immunoengineering represents a cutting-edge interdisciplinary domain that utilizes engineering tools to interrogate and modulate the immune system with unprecedented precision. This modulation involves either enhancing immune responses, as needed in cases of cancer or viral infections, or dampening them to treat autoimmune conditions. OCIE’s approach leverages this dual capability, seeking to systematically dissect immune mechanisms and develop innovative treatments tailored to diverse pathological contexts. The center is spearheaded by Wei Chen, Ph.D., an expert in cancer immunotherapy, and Chongle Pan, Ph.D., a leader in data science and computational biology, underscoring the center’s commitment to combining experimental and computational methodologies.

A critical infrastructure component of OCIE is the establishment of two synergistic research cores. The Immunomodulation Technology Core focuses on experimental laboratory work, providing researchers with advanced tools and methodologies to probe immune responses at the molecular and cellular levels. This core facilitates the development of novel immunotherapeutic strategies by enabling manipulation of immune cells and pathways in controlled laboratory settings. Complementing this, the Omics Data Science Core brings to bear state-of-the-art computational techniques and bioinformatics expertise. This core is dedicated to designing experiments, managing large-scale omics datasets, and applying machine learning algorithms to derive predictive models from complex immune system data.

The importance of integrating high-dimensional omics data with immunological experimentation arises from the sheer volume and complexity of information generated by modern biomedical research. Immunoengineering studies produce vast arrays of data spanning genomics, transcriptomics, proteomics, and metabolomics, which require sophisticated analytics to unravel the underlying biological insights. Through the synergy of experimental and computational cores, OCIE aims to build predictive frameworks that can forecast immune behavior under various therapeutic interventions, a critical step toward personalized medicine.

Dr. Wei Chen, leading the center, emphasizes the transformative potential of this integrated platform. Chen highlights his personal research in immunotherapy for late-stage cancer patients where the amalgamation of immunological insights with omics-driven data analysis has yielded innovative therapeutic avenues. OCIE aspires not only to be a hub of scientific innovation but also to serve as a collaborative platform for researchers across Oklahoma, fostering an ecosystem where discoveries rapidly translate into clinical applications that improve patient outcomes. This endeavor is positioned as a pioneering center nationally, with no existing comparable entity focusing on the convergence of immunomodulation and omics data science.

The Omics Data Science Core, under Chongle Pan’s guidance, is focused on harnessing artificial intelligence (AI), predictive modeling, and machine learning to provide actionable intelligence from immune system datasets. Because immune responses are highly dynamic and context-dependent, understanding them requires more than descriptive analysis—it requires predictive models that can simulate immune responses and predict therapeutic success. Pan’s work aims to democratize access to these computational tools, enabling researchers statewide to maximize the scientific yield of their immune-related studies.

OCIE also prioritizes the development of future scientific leaders by selecting and mentoring early-career investigators. Four junior faculty members have been appointed as research project leaders, each matched with experienced mentors from OU’s Norman and Health Sciences campuses. These young scientists spearhead innovative projects encompassing a broad range of immunoengineering challenges—from bat immunology related to coronavirus infection to sophisticated neuroimaging-guided immunotherapy in brain cancer, to computational and molecular investigations aimed at novel cancer vaccine design and understanding rare sarcoma immune microenvironments.

One project, led by Dr. Daniel Becker, explores the immune response of migratory bats to coronavirus infections, potentially offering vital clues to host-pathogen dynamics and natural viral resistance mechanisms. Dr. David Miller’s research focuses on glioblastoma, employing neuroimaging to guide immunotherapy approaches for one of the most aggressive and lethal brain tumors. Marmar Moussa’s work delves into T-cell receptor and antigen interactions, a fundamental aspect of developing effective peptide-based cancer vaccines. Meanwhile, Dr. Abdul Rafeh Naqash studies alveolar soft part sarcoma’s tumor immune microenvironment, identifying molecular vulnerabilities that could be therapeutically targeted.

Beyond project-specific research, OCIE fosters a vibrant scientific community through monthly seminars, interactive research roundtables, hands-on training workshops, and an annual symposium designed to catalyze interdisciplinary collaboration. A core mission of the center is to fund pilot research and promote team science, connecting basic immunologists, translational scientists, and clinicians to accelerate the journey from bench to bedside. This integrative approach aims to dismantle traditional silos and facilitate comprehensive understanding and manipulation of immune responses in multiple disease contexts.

The establishment of OCIE arrives at a strategic moment, given Oklahoma’s inclusion among the states benefiting from the NIH Institutional Development Award (IDeA) program. This program aims to enhance the research infrastructure in states that historically have received lower levels of NIH funding, thereby expanding national biomedical research capacity and equity. Through OCIE, Oklahoma becomes a vanguard for immunoengineering, reinforcing its scientific stature and capacity for biomedical innovation.

OCIE’s vision is nothing short of revolutionary. By converging immunology, engineering, and data science, the center establishes a model for precision immunomodulation. With capabilities spanning experimental manipulation and bioinformatic modeling, OCIE situates itself at the frontier of modern biomedicine, promising breakthroughs that could redefine immune system-based therapies. The center epitomizes the future of interdisciplinary biomedical research—where computation and experimentation coalesce to decode the immune system’s complexities and unlock new therapeutic vistas.

In summary, the University of Oklahoma’s Oklahoma Center for ImmunoEngineering leverages substantial NIH investment to create an unprecedented platform that integrates experimental immunomodulation technologies with advanced omics data science. Co-led by Drs. Wei Chen and Chongle Pan, OCIE is poised to make transformative advances in understanding and controlling immune function over diverse diseases such as cancer, viral infections, and autoimmune disorders. By supporting a new generation of interdisciplinary scientists and fostering collaboration, OCIE heralds a new era in immunoengineering, setting the stage for discoveries that hold the promise of vastly improved human health outcomes.

Subject of Research: Immunoengineering, Immunomodulation, Omics Data Science, Immunotherapy, Computational Biology

Article Title: University of Oklahoma Launches Pioneering Oklahoma Center for ImmunoEngineering with $11.5M NIH Award

News Publication Date: Not specified (most recent based on funding announcement)

Web References:
https://mediasvc.eurekalert.org/Api/v1/Multimedia/f8d658b4-8a4c-4e7e-b61d-c04c29ac2b93/Rendition/low-res/Content/Public

Image Credits: Jonathan Kyncl/University of Oklahoma

Keywords: Immunoengineering, Immunomodulation, Immune Regulation, Omics Data Science, Artificial Intelligence, Cancer Immunotherapy, Predictive Modelling, Machine Learning, Immune System, Biomedical Engineering, Systems Biology

The quest to augment cancer immunotherapy has long been challenged by the complexities of selectively activating the immune system while minimizing systemic toxicity. Traditional adjuvants—agents added to vaccines to enhance immune responses—often pose risks due to their non-specific activation of immune cells, which can result in adverse inflammatory reactions. This delicate balance between immune activation and safety is what makes the polypeptide sono-adjuvant particularly compelling. Designed to remain inert until exposed to ultrasound, this novel material acts as a molecular switch, enabling spatiotemporal precision in immune modulation that was previously unattainable.

At the heart of this advancement is the polypeptide sono-adjuvant itself, a sophisticated molecular construct engineered to respond robustly to ultrasound stimuli. Polypeptides, chains of amino acids, offer inherent biocompatibility and modularity, making them ideal candidates for biomedical applications. The team’s approach involved designing a polypeptide that can undergo conformational changes or release immunostimulatory elements upon ultrasonic activation. This method not only enhances localized immune responses but also mitigates peripheral immune activation, reducing unintended side effects.

Ultrasound, a non-invasive and widely accessible clinical tool, acts as the trigger for this system. By administering therapeutic ultrasound at targeted sites, clinicians can activate the sono-adjuvant precisely where immune activation is required, such as within tumor microenvironments or lymphoid tissues. This ultrasound-responsive feature introduces unprecedented control over immunotherapy regimens, paving the way for personalized and adaptive treatment protocols that respond dynamically to a patient’s condition.

One of the most notable implications of this technology is its ability to potentiate innate immunity, the body’s first line of defense against pathogens and aberrant cells. Innate immune cells, such as macrophages and natural killer cells, are crucial in recognizing and eliminating cancer cells. The ultrasound-activated polypeptide sono-adjuvant amplifies the activity of these cells, orchestrating a robust anti-tumor immune response that can synergize with adaptive immunity for sustained cancer eradication. This dual activation mode could be essential in overcoming tumor immune evasion mechanisms.

Moreover, the research demonstrates the practicality of integrating this sono-adjuvant into cancer vaccination platforms. Cancer vaccines typically aim to prime the adaptive immune system by presenting tumor-associated antigens; however, inducing strong and lasting immunity has proven difficult without robust adjuvant support. The ultrasound-activated polypeptide functions as an innovative adjuvant, amplifying vaccine-induced responses while allowing precise timing of immune engagement. This layer of control could significantly elevate vaccine efficacy, especially in tumors characterized by immunosuppressive microenvironments.

The mechanistic insights into the sono-adjuvant’s function reveal exciting facets of immune regulation. Under ultrasonic stimulation, the polypeptide undergoes structural rearrangements that expose immunostimulatory motifs or release small molecular signals. These molecular events trigger pattern recognition receptors (PRRs) on innate immune cells, setting off a cascade that leads to the production of pro-inflammatory cytokines and chemokines. This localized immune activation forms an inflammatory milieu conducive to effective antigen presentation, activation of dendritic cells, and priming of T-cells essential for long-term tumor control.

Importantly, the ultrasound parameters can be modulated to fine-tune the extent of immune activation. This tunability is crucial for balancing efficacy against potential tissue damage or overactivation of immune cells. Experimental models demonstrated that varying ultrasonic intensity, duration, and frequency resulted in controlled immune responses, underscoring the adaptability of this therapeutic platform. Such versatility ensures that treatments can be optimized on a patient-by-patient basis, embracing the goals of precision medicine.

Safety and biocompatibility have been central considerations in the development of this polypeptide sono-adjuvant. Given the challenges associated with immune-related adverse events in cancer immunotherapy, the researchers conducted extensive preclinical evaluations. These studies confirmed that absent ultrasonic activation, the polypeptide exhibited minimal immunogenicity and toxicity. Upon ultrasound-triggered activation, immune responses were localized and transient, supporting the potential for repeated administrations without systemic inflammation, a critical factor for clinical translation.

The research also explored the synergy between the sono-adjuvant and conventional cancer therapies. When combined with checkpoint inhibitors, a class of drugs that unleashes the immune system’s ability to attack tumors, the ultrasound-activated polypeptide markedly enhanced therapeutic outcomes. This synergy likely arises from the sono-adjuvant’s capacity to amplify innate immune activation and augment antigen presentation, thereby priming the tumor microenvironment to be more receptive to checkpoint blockade, a breakthrough for resistant or refractory cancers.

From a translational perspective, fabricating and deploying the polypeptide sono-adjuvant is feasible within existing clinical frameworks. Polypeptides can be synthesized with high purity and reproducibility, and ultrasound devices are already entrenched in medical practice for diagnostic and therapeutic applications. This compatibility accelerates the pathway from bench to bedside, promising rapid integration into clinical trials and eventual patient care modalities. Furthermore, the non-invasive nature of ultrasound offers advantages in patient comfort and compliance.

Beyond cancer, the principles underpinning this technology suggest wider applications in immunomodulation. Innate immunity plays central roles in various diseases, including infectious diseases, autoimmune disorders, and vaccine efficacy enhancement. The ultrasound-activated polypeptide system could be adapted to tune immune responses in these contexts, offering a versatile platform for controlling pathological or beneficial immunity with spatial and temporal precision.

The broader scientific community has lauded this study for its innovative merging of physical and biological sciences. By employing biophysical stimuli to control bioactive polymers, the researchers have expanded the toolkit available for immune engineering. This approach aligns with growing trends in mechanobiology and immunoengineering, where mechanical cues and stimuli-responsive materials are employed to interface intimately with biological systems, enabling opportunities previously considered unfeasible.

Moving forward, challenges remain in fully elucidating the molecular dynamics of the polypeptide’s ultrasound response and translating this knowledge into optimized formulations. Additionally, long-term studies in diverse tumor models and eventual human trials will be pivotal in assessing efficacy, safety, and durability of responses. Nonetheless, the promise of an immune activator that is controllable by an external and non-invasive stimulus heralds a new epoch in immune-oncology.

In conclusion, the development of the polypeptide sono-adjuvant heralds a sophisticated frontier in cancer immunotherapy, where precise regulation of innate immunity by ultrasound could overcome longstanding barriers to effective treatment. The convergence of ultrasound technology with rationally designed biomaterials provides a blueprint for future therapies that are both targeted and adaptable. As this technology advances toward clinical application, it may well redefine the paradigms of cancer vaccination and immune modulation, offering hope for improved survival and quality of life for patients worldwide.

Subject of Research: Polypeptide-based ultrasound-activated adjuvants for modulation of innate immunity and cancer vaccination therapy.

Article Title: Polypeptide sono-adjuvant for ultrasound-activatable regulation of innate immunity and cancer vaccination therapy.

Article References: Chen, F., Zhang, H., Li, S. et al. Polypeptide sono-adjuvant for ultrasound-activatable regulation of innate immunity and cancer vaccination therapy. Nat Commun (2025). https://doi.org/10.1038/s41467-025-66976-2

Image Credits: AI Generated